Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

The geopolitical incidents of the recent past as well as the pandemic have not really helped cost pressure: Tambe

Riding on strong growth numbers for its biologics business, and growing market share for its interchangeable biosimilar insulin Glargine in the US market, Biocon Biologics is now eyeing more. Speaking to Sohini Das, Shreehas Tambe, deputy chief executive officer (deputy CEO), Biocon Biologics, unveils how the firm is also strengthening its India insulins team now.

Fiscal 2022 has seen many milestones. How do you look back at the year?

On the back of a strong demand and seamless execution in FY22, our (Biocon Biologics) Q4 revenues grew just under 50 per cent year on year (YoY), and our annual revenues